Gilead (GILD) Announced Interim Phase 2 Data on Hepatitis Drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Notable ETF Movers of the Day 11/12: (IBB) Higher; (XLU) (ITB) Lower
November 12, 2012 12:58 PM ESTGainers:
iShares Nasdaq Biotechnology (Nasdaq: IBB) gained 2 percent to 132.57. The move is tied to shares of Gilead Sciences (Nasdaq: GILD) which gained 12 percent on positive results for its drug combo 7977/5885 for treatment of hepatitis C. Shares of... More
Deutsche Bank Maintains Buy on Gilead Sciences (GILD) after Strong Hepatitis C Combo Data
November 12, 2012 8:39 AM ESTDeutsche Bank reiterated its Buy rating and $75 price target on Gilead Sciences (NASDAQ: GILD) following positive data from the '7977/'5885 combo in treatment-naïve genotype 1 Hepatitis C patients, showing 100 percent (n=25/25) remained HCV RNA undetectable four weeks after completing therapy (SVR4).
Commenting on... More
